- Home
- GIGM vs INDP Comparison
GIGM vs INDP Comparison
Compare GIGM & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- INDP
- Stock Information
- Founded
- GIGM 1998
- INDP 2000
- Country
- GIGM Taiwan
- INDP United States
- Employees
- GIGM N/A
- INDP N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- INDP Health Care
- Exchange
- GIGM Nasdaq
- INDP Nasdaq
- Market Cap
- GIGM 17.0M
- INDP 6.0M
- IPO Year
- GIGM 2000
- INDP N/A
- Fundamental
- Price
- GIGM $1.79
- INDP $2.57
- Analyst Decision
- GIGM
- INDP Strong Buy
- Analyst Count
- GIGM 0
- INDP 2
- Target Price
- GIGM N/A
- INDP $238.00
- AVG Volume (30 Days)
- GIGM 22.4K
- INDP 218.3K
- Earning Date
- GIGM 10-29-2025
- INDP 11-11-2025
- Dividend Yield
- GIGM N/A
- INDP N/A
- EPS Growth
- GIGM N/A
- INDP N/A
- EPS
- GIGM N/A
- INDP N/A
- Revenue
- GIGM $3,250,000.00
- INDP N/A
- Revenue This Year
- GIGM N/A
- INDP N/A
- Revenue Next Year
- GIGM N/A
- INDP N/A
- P/E Ratio
- GIGM N/A
- INDP N/A
- Revenue Growth
- GIGM N/A
- INDP N/A
- 52 Week Low
- GIGM $1.30
- INDP $2.22
- 52 Week High
- GIGM $1.89
- INDP $58.24
- Technical
- Relative Strength Index (RSI)
- GIGM 64.65
- INDP 23.80
- Support Level
- GIGM $1.61
- INDP $2.22
- Resistance Level
- GIGM $1.89
- INDP $2.86
- Average True Range (ATR)
- GIGM 0.09
- INDP 0.61
- MACD
- GIGM 0.02
- INDP -0.07
- Stochastic Oscillator
- GIGM 76.79
- INDP 6.09
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.